Hemostemix and firefly neuroscience's brain network analytics (bna(tm)) engage to complete phase 1 vascular dementia clinical trial of acp-01

A growing body of clinical evidence supports the use of firefly's fda-cleared bna(tm) platform to study acp-01 as a treatment for vascular dementia calgary, alberta--(newsfile corp. - march 6, 2025) - hemostemix inc. (tsxv: hem) (otcqb: hmtxf) (fse: 2vf0) ("hemostemix" or "hem"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with firefly neuroscience, inc. (nasdaq: aiff) ("firefly"), an artificial intelligence ("ai") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. hemostemix and firefly will study brain wave activity in up to 100 patients before and after treatment with acp-01 at baseline, 3-months, and 6-months post-treatment (the "phase 1").
AIFF Ratings Summary
AIFF Quant Ranking